Hemophilia B gene therapy Hemgenix approved in Switzerland
Hemgenix (etranacogene dezaparvovec), the first and only one-time gene therapy approved for hemophilia B, has been approved in…
Articles by Marisa Wexler, MS
Approved Roctavian ‘liberating’ for 1st US patient treated outside trials
In the final days of 2023, an adult with hemophilia A named Maxwell became the first person in the…
Top 10 hemophilia stories of 2023
Hemophilia News Today brought you coverage of the latest developments in research and advances in treatments for hemophilia…
Device developed that can diagnose hemophilia A in emergencies
Scientists in Taiwan have created a new point-of-care device to diagnose hemophilia type A and determine a person’s blood…
Healthcare costs similar for patients on Adynovate, Eloctate: Study
Healthcare costs are comparable for male patients with hemophilia A who are treated with either Adynovate (rurioctocog alfa pegol)…
Hemgenix lowers bleeding rates, replacement therapy use
Bleeding rates and the use of replacement therapies among men with severe or moderately severe hemophilia B remain low…
Improvements in ‘mood/emotions’ reported for children on Altuviiio
The parents of most children with severe hemophilia A who took part in the XTEND-Kids clinical trial of…
Marstacimab up for approval for hemophilia in US, Europe
The once-weekly injection therapy marstacimab is being considered for approval in both the U.S. and Europe for people with…
Dosing begins in Phase 1/2a trial of optimized gene therapy for hem A
A first patient has been dosed in a Phase 1/2a clinical trial that’s assessing the safety and preliminary efficacy of…
Antibody test for Roctavian cleared under new, stringent EU rules
AAV5 DetectCDx, a companion diagnostic test used to determine patient eligibility for the hemophilia A gene therapy Roctavian…